What Аскорил Экспекторант Treats: Main Uses and Benefits

The primary therapeutic use of this combination is relevant across domains where additional symptomatic support is needed to address clusters of symptoms that appear suddenly or intensify. It is used in situations involving certain distressing symptoms that interfere with daily functioning. Its application is relevant for conditions where bronchospasm, mucus plugging, and problems of expectoration coexist.

This combination is considered relevant for conditions where symptoms may intensify temporarily, such as conditions involving episodic or fluctuating manifestations. The medication is commonly used to help with symptom clusters that may become intense or disruptive, including wheezing and productive cough. It is applied across domains where additional symptomatic support is needed to address symptom clusters related to physical discomfort. This usage is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability when symptoms are more noticeable.

---

Supportive Relief and Comfort

The medication is relevant for easing symptoms that create noticeable functional strain, offering symptomatic relief that helps patients cope more steadily during difficult episodes.

“This combination is applied in clinical settings that involve acute or unstable symptom patterns, assisting with maintaining functional stability when symptoms are more noticeable.”

---

Quick Fact: Relief for Dual Respiratory Discomfort

Symptom Category	Therapeutic Benefit
Airway Constriction (Wheezing, Chest Tightness)	Supports eased breathing and reduced functional strain.
Mucus Retention (Productive Cough, Phlegm)	Helps address symptom clusters related to physical discomfort.

Regulatory References

1. Rwanda FDA drug summary

Eligibility Map: Who can and cannot use Аскорил экспекторант — Official Regulatory Information

The eligibility for this fixed-dose combination product, which typically contains Salbutamol, Bromhexine, and Guaifenesin, is defined by specific population rules and contraindications documented by national regulatory authorities.

---

Eligibility Scope	Status Defined by Regulators
Populations for Whom Use is Contraindicated	Hypersensitivity to any component (Salbutamol, Bromhexine, Guaifenesin), severe cardiac disorders (e.g., tachyarrhythmia), thyrotoxicosis, decompensated diabetes mellitus, or active peptic ulceration.
Age-Related Eligibility Rules	Contraindicated in children under 2 years of age. Use in children aged 2 to 6 years is conditional and requires medical advice. Use is generally established for adults and adolescents (12 years and older).
Pregnancy and Lactation Eligibility	Contraindicated or not recommended during both pregnancy and lactation in many official labels, as the benefits must clearly outweigh the potential risks.

---

Eligibility-Related Restrictions

Use of the medicine requires caution in patients with specific chronic conditions, including hypertension, controlled diabetes mellitus, a history of peptic ulcers, seizure disorders, and liver or kidney impairment. These restrictions signal the need for medical supervision to assess suitability. Individuals with established eligibility are generally adults and adolescents (12 years and older) who do not present with any absolute contraindications.

The official prescribing information for the combination of Salbutamol, Bromhexine, and Guaifenesin documents specific interaction patterns with other medicines and substances. These interactions are classified based on pharmacodynamic effects, exposure modification, or interference with diagnostic procedures.

Contraindicated and Restricted Combinations

Co-administration is generally not recommended with medicines that may potentiate adverse effects or antagonize therapeutic action:

• Non-selective beta-blocking drugs (e.g., Propranolol) are restricted due to mutual opposition of the bronchodilator effect.
• Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants should be avoided due to the documented risk of potentiating the vascular effects of the Salbutamol component.
• Cough suppressants and other antitussives are restricted because they may hinder the expulsion of respiratory secretions diluted by the expectorant component.
• Other oral sympathomimetic agents should not be co-administered due to the risk of additive sympathomimetic effects.

Interactions Requiring Caution

• Diuretics and Corticosteroids co-administered with this product increase the risk of hypokalemia, based on documented additive pharmacodynamic effects.
• The Bromhexine component promotes the penetration of certain Antibiotics (e.g., Erythromycin) into pulmonary tissue, an officially noted exposure modification.
• Alcohol consumption should be avoided due to the risk of additive central nervous system depressant effects.
• The Guaifenesin metabolite may cause colorimetric interference with laboratory determinations of Urinary VMA and 5-HIAA if urine is collected within 24 hours of administration. Caution is also recommended in subjects with severe renal or hepatic impairment.

The mechanism of action for this preparation is based on the simultaneous, complementary effects of three distinct pharmacological domains that modulate both the physical diameter of the airways and the physicochemical properties of the retained secretions.

---

Modulation of Airway Smooth Muscle Tone

This domain focuses on the component Salbutamol, which acts as a selective agonist for beta2-adrenergic receptors located on the bronchial smooth muscle. Activation of this receptor initiates a signaling cascade that elevates intracellular cyclic AMP (cAMP) and reduces calcium Ca^2+ concentration, leading directly to the relaxation of the airway smooth muscle and causes a consequent physiological reduction in airway resistance.

---

Physicochemical Modification of Bronchial Secretions

This domain involves the combined actions of Bromhexine and Guaifenesin. Bromhexine exerts a mucolytic effect by depolymerizing the acidic mucopolysaccharide fibers, which structurally reduces the mucus viscosity. Simultaneously, Guaifenesin stimulates a gastropulmonary vagal reflex, increasing the output of thin, serous fluid into the bronchial lumen. These coordinated actions result in secretions exhibiting lower viscosity and greater volume.

---

Integrated Synergy for Enhanced Mucus Clearance

The combination mechanism links the reduced airway resistance to the modification of secretion properties. This synergy coordinates the physiological effects of open airways with a more mobile substance. This coordination facilitates the mobilization and physiological clearance of accumulated bronchial contents from the respiratory system.

Official Administration Guidelines

The administration of this fixed-dose combination product is governed by protocols specifying the route, frequency, dose volumes, and procedural steps, based on official prescribing information.

---

Administration Scope

Instruction Domain	Official Labeled Requirement
Route of Administration	Oral administration (per os) as a liquid solution or syrup.
Standard Adult Dosing	The typical administration volume for adults is 10 mL to 20 mL per dose.
Dosing Frequency	The medicine is officially prescribed for use three times daily.
Timing	May be administered independently of food intake (with or without food).
Preparation	The container must be shaken well prior to administration of each dose.

---

Age-Group Administration Rules

Dosing volumes are adjusted for the pediatric population according to age-specific schedules detailed in official documents.

• Children 6 to 12 years: The usual dose is 10 mL per dose, administered three times daily.
• Children 2 to 6 years: The usual dose is 5 mL per dose, administered three times daily.
• Children Under 2 years: Use of this combination product is generally not recommended as safety and effectiveness have not been adequately demonstrated.

Procedural Constraints

For accurate administration, the specific volume must be measured using a calibrated measuring device. The official protocol mandates that the prescribed daily maximum dose is not to be exceeded. This product is intended for short-term administration, tied to the acute need for supportive measures. If a dose is missed, guidance instructs to continue with the next scheduled dose and not to take a double dose.

Research Evidence / Overview of Studies for Аскорил Экспекторант

This overview summarizes the available research regarding the clinical evaluation of the combination medicine. It details the types of studies conducted and what outcomes they examined, as reported in scientific literature. This section is a strictly descriptive summary of the research landscape and provides no clinical advice or treatment recommendations.

---

Evidence for Use in Productive Cough and Acute Bronchial Conditions

The active ingredient combination was studied for conditions where research examined patient-reported outcomes related to productive cough in acute and chronic bronchial disorders. These research contexts involve situations where symptoms may vary in intensity, such as acute bronchitis and acute exacerbations of certain chronic respiratory disorders.

Studies for this fixed-dose combination (FDC) were conducted during periods of increased symptom activity. Researchers explored how symptoms evolved in the observed populations, and the findings describe patterns observed in these short-term studies. The evidence describes symptom patterns observed, including those related to the physical discomfort of productive cough.

---

Types of Studies and Outcomes Examined

The research base is built upon two main types of studies. The first type includes Randomized Controlled Comparative Trials (RCTs). These studies were designed to compare the combination against formulations containing only two of the active ingredients, rather than an inactive control (placebo). The second type is large Multicenter Non-Interventional Studies, which reflect how the combination is used in daily practice by observing responses over defined time intervals.

Researchers monitored outcomes related to physical discomfort. These studies examined data from patient-reported scales for cough frequency and severity. Studies also monitored physiological strain or stress by examining changes in sputum characteristics, such as how easily secretions could be expelled. The findings describe how patients reported their experience during the short period of observation.

---

Studies in Specific Patient Groups

The combination was evaluated in specific populations, and findings describe group patterns observed in these studies.

Research has explored the use of the combination in adults presenting with cycles of stability and flare-ups, including those with diagnoses like acute bronchitis and Grade I–II Chronic Obstructive Pulmonary Disease (COPD) exacerbations. Additionally, the combination was studied for use in children typically over the age of three years who were presenting with acute respiratory illnesses. The research provides context for the outcomes observed in these groups.

---

Long-Term Evidence and Follow-up Duration

Research exploring short-term symptom changes was observed in studies that typically limited follow-up durations to the acute phase of illness, often ranging from one to two weeks.

The duration of observation in the research does not characterize sustained patterns of use for chronic management, as studies primarily focused on defined time intervals covering the acute phase. Long-term effects are not fully established. Limited information exists for long-term outcomes. Study results reflect the specific conditions and limited time intervals under which they were conducted.

---

Key Evidence Gaps and Areas of Uncertainty

The body of evidence is categorized as moderate, and research describes limitations that remain relevant in the scientific literature.

• Placebo Comparisons: Comparative evidence is lacking for the specific combination against an inactive control (placebo). The available data often comes from comparisons against other active treatments.
• Duration Limitations: As follow-up durations were limited, data for sustained therapeutic use or patterns of use in chronic conditions remain insufficient.
• Evidence Consistency: While research describes patterns related to short-term changes, evidence quality varies across studies, and data for certain specific subgroups remain uncertain. The research describes existing data limitations and areas where more study is needed for this combination.

Key Studies & References

1. Ascoril Expectorant - Summary of Product Characteristics (SmPC) - Rwanda FDA

Common questions about Аскорил экспекторант (FAQ)

Q: What is Ascoril Expectorant used for?

Ascoril Expectorant is a combination medicine used to provide relief from a wet, chesty cough associated with conditions like bronchitis, asthma, or chronic obstructive pulmonary disease (COPD). It helps to thin and loosen mucus, making it easier to cough up, and relaxes the muscles in the airways to ease breathing.

Q: How does Ascoril Expectorant work?

Ascoril Expectorant contains three main active ingredients that work together:

• Salbutamol: This is a bronchodilator that relaxes the muscles in the walls of the airways (bronchi), opening them up and making it easier to breathe.
• Bromhexine: This is a mucolytic agent. It works by breaking down and thinning the thick mucus (sputum) in the respiratory passages, reducing its stickiness and viscosity.
• Guaifenesin: This is an expectorant. It increases the volume of fluid in the respiratory tract, which helps to loosen and thin the mucus, promoting its clearance by coughing.

Q: What are the common side effects of Ascoril Expectorant?

Some common side effects may include:

• Nervousness or Tremor: Due to the Salbutamol component.
• Headache
• Dizziness
• Nausea or Vomiting
• Increased heart rate (palpitations)

These side effects are usually mild and temporary. If any side effect persists or worsens, consult a healthcare provider.

Q: Can Ascoril Expectorant be taken during pregnancy?

Information on the use of Ascoril Expectorant during pregnancy is limited, and it should generally be avoided unless specifically prescribed by a healthcare professional who has weighed the potential benefits against the possible risks to the fetus. The Salbutamol component is often used cautiously in pregnancy, especially near term.

Q: Can I take Ascoril Expectorant if I have a heart condition?

Caution is advised when taking Ascoril Expectorant if you have a pre-existing heart condition, such as an irregular heartbeat, high blood pressure, or coronary artery disease. Salbutamol can stimulate the heart and may worsen these conditions. You should inform your doctor about any heart problems before starting this medication.

Q: Does Ascoril Expectorant contain an antibiotic?

No, Ascoril Expectorant does not contain an antibiotic. It is a combination of a bronchodilator, a mucolytic, and an expectorant. It is used to manage the symptoms of a cough and respiratory congestion, but it does not treat bacterial infections.

Q: Is Ascoril Expectorant the same as an ordinary cough syrup?

Ascoril Expectorant is not the same as a simple cough syrup. It is a multi-ingredient formulation that not only helps suppress or clear a cough but also contains a bronchodilator (Salbutamol) to open the airways. Simple cough syrups might only contain a single expectorant, a cough suppressant, or a demulcent.

Storage and Disposal of Ascoril Expectorant

This information details the mandatory storage, handling, and disposal instructions as required by regulatory labeling.

---

Storage Conditions

Ascoril Expectorant must be stored at a temperature below 30 C. The product must be kept in a clean and dry place and be protected from both light and moisture. The syrup formulation must not be frozen.

Packaging and Safety

The medicine should remain in its original container and the container must be kept tightly closed. For safety, the product is required to be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine must be disposed of in accordance with local requirements. The regulatory labeling specifies that the liquid formulation should not be flushed down the toilet or poured into the drain; follow the guidance of a local pharmacist or waste authority for safe disposal.